Although it was shown that dihydrotestosterone (DHT) down-regulated SMP30/regucalcin mRNA expression in prostate cancer LNCaP cells, this inhibitory effect was abolished by flutamide, an AR antagonist, suggesting that down-regulation of SMP30/regucalcin expression by DHT is through AR modulation20. This evidence concerns the gene AR and prostate cancer.